FDA Wants More Analysis From BioMimetic On Augment Bone Graft
This article was originally published in The Gray Sheet
Executive Summary
Agency issues “not approvable” letter seeking more detailed analysis from the firm’s already-completed pivotal trial, but FDA is not asking for a new clinical study, BioMimetic stressed.